Dosing & PK parameters

Dosing & PK parameters

Explore dosing and PK parameters of KOVALTRY® in adults (18 years old)

Dosing with KOVALTRY® for routine prophylaxis1

Individualize the patient's dose based on clinical response
  Dose Regimen
Adults 20–40 IU/kg 2x/week or 3x/week

PK parameters of KOVALTRY® in the LEOPOLD I trial (arithmetic mean ± SD)1

PK parameters were measured using chromogenic substrate assay after a single 50 IU/kg dose of KOVALTRY® in 21 previously treated patients ≥18 years old

Parameter (unit) 18 years
AUC (IUh/dL) 2103.4 ± 702.8
Cmax (IU/dL) 133.1 ± 20.4
t1/2 (h) 14.2 ± 3.5
MRTIV (h) 19.9 ± 4.9
Vss (dL/kg) 0.50 ± 0.11
CL (dL/h/kg) 0.027 ± 0.010

AUC=area under the curve.
Cmax=maximum concentration.
LEOPOLD=Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease.
MRTIV=mean residence time after an intravenous administration.

SD=standard deviation.
Vss=apparent volume of distribution at steady state.


KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY® is not indicated for the treatment of von Willebrand disease.


KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY®. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY® if symptoms occur and seek immediate emergency treatment.

KOVALTRY® may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation can occur following administration of KOVALTRY®. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY® is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥3%) were headache, pyrexia, and pruritus.

For additional important risk and use information, please see full Prescribing Information.

Reference: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2016.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

© 2017 Bayer.   All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.
Advate is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

Site Last Modified 09/2017